Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Bibliographic Details
Main Authors:	Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose
Format:	Online
Language:	English
Published:	Lippincott Williams & Wilkins 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224589/

Similar Items

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
by: Douillard, J-Y, et al.
Published: (2014)

Unexpected responses to EGFR inhibition in NSCLC
by: Stella, Giulia M., et al.
Published: (2015)

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
by: Cragg, Mark S, et al.
Published: (2007)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
by: Xin, Shuang, et al.
Published: (2015)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
by: Singh, Charu
Published: (2014)

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
by: Bokobza, Sivan M., et al.
Published: (2014)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang, Fen, et al.
Published: (2012)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
by: Kuiper, J L, et al.
Published: (2016)

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
by: Gahr, S, et al.
Published: (2013)

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report
by: Kamila, Wojas-Krawczyk, et al.
Published: (2013)

Sulforaphane attenuates EGFR signaling in NSCLC cells
by: Chen, Chi-Yuan, et al.
Published: (2015)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
by: He, Peng, et al.
Published: (2013)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
by: Ellison, Gillian, et al.
Published: (2013)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang, Wen-Ping, et al.
Published: (2012)

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
by: Dufort, Sandrine, et al.
Published: (2011)

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
by: Zhang, Xinji, et al.
Published: (2012)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
by: Russo, Alessandro, et al.
Published: (2015)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
by: Wang, Zhijie, et al.
Published: (2015)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
by: Yan, Han, et al.
Published: (2015)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
by: Paz-Ares, Luis, et al.
Published: (2014)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
by: Gow, Chien-Hung, et al.
Published: (2005)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan, Ying, et al.
Published: (2012)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
by: Wu, Xuan, et al.
Published: (2013)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
by: Troiani, Teresa, et al.
Published: (2016)

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
by: Che, Ting-Fang, et al.
Published: (2015)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
by: Melosky, Barbara
Published: (2014)

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
by: Gaber, Rania, et al.
Published: (2014)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
by: Karachaliou, Niki, et al.
Published: (2014)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wu, Wen-Shuo, et al.
Published: (2014)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
by: Noronha, Vanita, et al.
Published: (2014)

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study
by: Hantson, Inge, et al.
Published: (2014)

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
by: Pugh, Trevor J, et al.
Published: (2007)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
by: Pan YH, et al.
Published: (2018-08-01)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
by: Wang, Debby D., et al.
Published: (2015)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
by: Krawczyk, Paweł, et al.
Published: (2015)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
by: Presutti, Dario, et al.
Published: (2015)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
by: Wang, Shuhang, et al.
Published: (2015)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
by: Wu, Hong, et al.
Published: (2015)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
by: Brzezniak, Christina, et al.
Published: (2016)